Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Summary

This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

Timeline

Start

2025-01-03

Primary completion

2026-04

Completion

2026-05

Drugs

Indications